1. Syrma SGS Technology:
Motilal Oswal reiterates its ‘Buy’ rating on this electronic manufacturing company, with a target price of Rs 1,300, an upside of 11.4%. Analysts Sumant Kumar and Meet Jain remain positive on Syrma SGS as the company shifts from low-margin assembly work to higher-value electronics manufacturing. It is increasing its presence in automotive, industrial equipment, medical devices and defence electronics, while reducing its dependence on consumer electronics and telecom products. These higher-value businesses now contribute more than half of their Rs 6,600 crore order book.
A key growth driver is the company’s entry into printed circuit board (PCB) manufacturing through a joint venture with South Korea-based Shinhyup Electronics. India currently imports 88% of its PCBs, offering domestic manufacturers a huge opportunity. Management expects this business to generate Rs 300 crore in revenue by FY28, with a long-term potential of Rs 2,500 crore.
Analysts Nikhil Chouhan and Chirag Shah believe Syrma perfectly aligns with the government's push for local electronics manufacturing. They estimate revenue, EBITDA, and net profit will grow at a CAGR of 32%, 35%, and 39%, respectively, through FY28.
2. Narayana Hrudayalaya:
Prabhudas Lilladher maintains its ‘Buy’ rating on this healthcare provider, raising the target price to Rs 2,250 for a 16.8% upside. Narayana Hrudayalaya delivered robust Q4FY26 results. Revenue soared 74.6% YoY, and net profit rose 13.5%. Analysts Param Desai and Sanketa Kohale note that this growth has come from operational improvements in India and the Cayman Islands, alongside the consolidation of its UK subsidiary.
A better patient mix boosted the India market, raising average revenue per bed by 10%. Meanwhile, Cayman operations increased revenue by 13%, excluding the insurance business. Margin performance looked mixed. Consolidated margins dropped 460 basis points; however, India's margins expanded 400 bps, thanks to a higher contribution of complex medical cases.
The Bengaluru cluster remains the key growth driver, led by leadership in robotic cardiac surgeries and pediatric bone marrow transplants.
Management revealed aggressive expansion plans. They aim to boost bed capacity by 41% over the next three years across Bengaluru, Kolkata and Raipur. To achieve this, they will invest Rs 3,000 crore in domestic upgrades and Rs 460 crore in fresh acquisitions. Analysts expect rising patient inflows to generate 24.4% revenue and 25.4% net profit CAGRs through FY28.
3. AIA Engineering:
ICICI Direct upgrades this industrial machinery parts maker to a ‘Buy’ call, with a target price of Rs 5,285 per share, an upside of 16.1%. Analysts Chirag J Shah and Dilip Pandey turned positive after AIA Engineering reported robust Q4FY26 results. Strong sales volumes and better pricing drove a 9.4% YoY increase in revenue. EBITDA jumped 17.4%. Selling more high-value products expanded the EBITDA margin by 200 basis points.
Management said it is making progress in expanding its business with mining companies. AIA recently installed a new grinding system at a South American mine. The system performed well and helped the company win a second order from the same customer. Management states the new system can increase ore processing capacity by 15% while consuming less electricity, helping mining companies improve efficiency and lower costs.
Shah and Pandey see AIA Engineering as well-positioned to benefit from more mining companies shifting to its high-chrome grinding media. Mining operations use these specific tools to crush and grind ore. The company is currently using only about 55% of its production capacity and holds cash reserves of around Rs 4,300 crore, giving it room to expand.
4. Rainbow Childrens Medicare:
Geojit BNP Paribas initiates coverage on this healthcare facilities company with a ‘Buy’ rating and a target price of Rs 1,679, indicating a 26.2% upside. Rainbow reported healthy Q4FY26 results. Surging demand across pediatric, obstetrics and specialty healthcare services pushed revenue up 20.9% YoY. Net profit climbed 36.8%, driven by lower tax expenses.
Analyst Antu Eapan Thomas sees Rainbow as a highly attractive investment, owing to its consistent growth, funding strategy and low valuation. He notes that improving occupancy rates and a better patient mix will drive revenue and earnings growth, potentially triggering further stock upgrades.
Rainbow currently operates as a South-centric franchise. However, it plans to shift into a national pediatric and perinatal platform by increasing bed capacity 41% by FY29. This aggressive expansion will reduce South India’s share of total beds to 74% from 93%.
Thomas points out that this multi-hub strategy limits geographic risk, offsets seasonal dips in pediatric care, and secures long-term revenue growth. He expects new medical services and deeper tertiary care options to help Rainbow achieve a 15% revenue CAGR through FY28.
5. NLC India:
Axis Direct upgrades this power and mining company to a ‘Buy’ call, with a target price of Rs 385 per share, an upside of 10.3%. Analysts Aditya Welekar and Keval Barot turned bullish as NLC India enters a new growth phase, driven by expanding power generation, higher coal production and a ramp-up in renewable energy capacity.
One of the key growth drivers is the Ghatampur thermal power plant. The third and final unit of the project is expected to start operations in June 2026, making the entire 1,980 MW plant fully operational. The company has also begun mining at the Pachwara South coal block, which started production in March 2026. The mine is projected to produce around 2 million tonnes of coal in FY27, with annual output eventually increasing to 9 million tonnes.
Welekar and Barot note NLC's aggressive long-term goals. The company plans to more than double its mining capacity to 104 million tonnes per annum by 2030. It also aims to grow thermal power capacity from 5,960 MW to 10,020 MW, and expand renewable energy by over five times. To fund these projects, the company plans to invest over Rs 1 lakh crore.
Note: These recommendations are from various analysts and are not recommendations by Trendlyne.
(You can find all analyst picks here)